UK Markets open in 1 hr 50 mins

Global Influenza Medication Market to Reach $1.9 Billion by 2027

ReportLinker
ReportLinker

In the changed post COVID-19 business landscape, the global market for Influenza Medication estimated at US$1. 7 Billion in the year 2020, is projected to reach a revised size of US$1. 9 Billion by 2027, growing at a CAGR of 1.

New York, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Influenza Medication Industry" - https://www.reportlinker.com/p06044677/?utm_source=GNW
5% over the analysis period 2020-2027. Zanamivir, one of the segments analyzed in the report, is projected to record a 0.9% CAGR and reach US$118.3 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Oseltamivir segment is readjusted to a revised 1.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $456.5 Million, While China is Forecast to Grow at 2.4% CAGR

The Influenza Medication market in the U.S. is estimated at US$456.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$327.4 Million by the year 2027 trailing a CAGR of 2.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1% and 1.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$225.2 Million by the year 2027.



Peramivir Segment to Record 1.5% CAGR

In the global Peramivir segment, USA, Canada, Japan, China and Europe will drive the 1.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$176.4 Million in the year 2020 will reach a projected size of US$195.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 1.5% CAGR through the analysis period.

Select Competitors (Total 46 Featured) -
Biostar Pharmaceuticals
Daiichi Sankyo Co., Ltd.
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Natco Pharma Limited
Sandoz International GmbH
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.


Read the full report: https://www.reportlinker.com/p06044677/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Influenza Medication - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Influenza Medication by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Influenza Medication by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Influenza Medication by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Zanamivir by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Zanamivir by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Zanamivir by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Oseltamivir by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Oseltamivir by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Oseltamivir by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for
Peramivir by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Peramivir by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Peramivir by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for
Amantadine by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Amantadine by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Amantadine by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for
Rimantadine by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Rimantadine by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Rimantadine by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for
Other Products by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Other Products by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Other Products by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for
Hospitals by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for
Clinics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Clinics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Clinics by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis for
Pharmacies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Pharmacies by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Pharmacies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027

Table 31: World Influenza Medication Market Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2027

III. MARKET ANALYSIS

UNITED STATES
Influenza Medication Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2022 (E)
Table 32: USA Recent Past, Current & Future Analysis for
Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 33: USA Historic Review for Influenza Medication by
Product - Zanamivir, Oseltamivir, Peramivir, Amantadine,
Rimantadine and Other Products Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 34: USA 15-Year Perspective for Influenza Medication by
Product - Percentage Breakdown of Value Sales for Zanamivir,
Oseltamivir, Peramivir, Amantadine, Rimantadine and Other
Products for the Years 2012, 2021 & 2027

Table 35: USA Recent Past, Current & Future Analysis for
Influenza Medication by Distribution Channel - Hospitals,
Clinics and Pharmacies - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 36: USA Historic Review for Influenza Medication by
Distribution Channel - Hospitals, Clinics and Pharmacies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 37: USA 15-Year Perspective for Influenza Medication by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Pharmacies for the Years 2012, 2021 &
2027

CANADA
Table 38: Canada Recent Past, Current & Future Analysis for
Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 39: Canada Historic Review for Influenza Medication by
Product - Zanamivir, Oseltamivir, Peramivir, Amantadine,
Rimantadine and Other Products Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 40: Canada 15-Year Perspective for Influenza Medication
by Product - Percentage Breakdown of Value Sales for Zanamivir,
Oseltamivir, Peramivir, Amantadine, Rimantadine and Other
Products for the Years 2012, 2021 & 2027

Table 41: Canada Recent Past, Current & Future Analysis for
Influenza Medication by Distribution Channel - Hospitals,
Clinics and Pharmacies - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 42: Canada Historic Review for Influenza Medication by
Distribution Channel - Hospitals, Clinics and Pharmacies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 43: Canada 15-Year Perspective for Influenza Medication
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospitals, Clinics and Pharmacies for the Years 2012, 2021 &
2027

JAPAN
Influenza Medication Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2022 (E)
Table 44: Japan Recent Past, Current & Future Analysis for
Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 45: Japan Historic Review for Influenza Medication by
Product - Zanamivir, Oseltamivir, Peramivir, Amantadine,
Rimantadine and Other Products Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 46: Japan 15-Year Perspective for Influenza Medication by
Product - Percentage Breakdown of Value Sales for Zanamivir,
Oseltamivir, Peramivir, Amantadine, Rimantadine and Other
Products for the Years 2012, 2021 & 2027

Table 47: Japan Recent Past, Current & Future Analysis for
Influenza Medication by Distribution Channel - Hospitals,
Clinics and Pharmacies - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 48: Japan Historic Review for Influenza Medication by
Distribution Channel - Hospitals, Clinics and Pharmacies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 49: Japan 15-Year Perspective for Influenza Medication by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Pharmacies for the Years 2012, 2021 &
2027

CHINA
Influenza Medication Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2022 (E)
Table 50: China Recent Past, Current & Future Analysis for
Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 51: China Historic Review for Influenza Medication by
Product - Zanamivir, Oseltamivir, Peramivir, Amantadine,
Rimantadine and Other Products Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 52: China 15-Year Perspective for Influenza Medication by
Product - Percentage Breakdown of Value Sales for Zanamivir,
Oseltamivir, Peramivir, Amantadine, Rimantadine and Other
Products for the Years 2012, 2021 & 2027

Table 53: China Recent Past, Current & Future Analysis for
Influenza Medication by Distribution Channel - Hospitals,
Clinics and Pharmacies - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 54: China Historic Review for Influenza Medication by
Distribution Channel - Hospitals, Clinics and Pharmacies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 55: China 15-Year Perspective for Influenza Medication by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Pharmacies for the Years 2012, 2021 &
2027

EUROPE
Influenza Medication Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2022 (E)
Table 56: Europe Recent Past, Current & Future Analysis for
Influenza Medication by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 57: Europe Historic Review for Influenza Medication by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 58: Europe 15-Year Perspective for Influenza Medication
by Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2021 & 2027

Table 59: Europe Recent Past, Current & Future Analysis for
Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 60: Europe Historic Review for Influenza Medication by
Product - Zanamivir, Oseltamivir, Peramivir, Amantadine,
Rimantadine and Other Products Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 61: Europe 15-Year Perspective for Influenza Medication
by Product - Percentage Breakdown of Value Sales for Zanamivir,
Oseltamivir, Peramivir, Amantadine, Rimantadine and Other
Products for the Years 2012, 2021 & 2027

Table 62: Europe Recent Past, Current & Future Analysis for
Influenza Medication by Distribution Channel - Hospitals,
Clinics and Pharmacies - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 63: Europe Historic Review for Influenza Medication by
Distribution Channel - Hospitals, Clinics and Pharmacies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 64: Europe 15-Year Perspective for Influenza Medication
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospitals, Clinics and Pharmacies for the Years 2012, 2021 &
2027

FRANCE
Influenza Medication Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2022 (E)
Table 65: France Recent Past, Current & Future Analysis for
Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 66: France Historic Review for Influenza Medication by
Product - Zanamivir, Oseltamivir, Peramivir, Amantadine,
Rimantadine and Other Products Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 67: France 15-Year Perspective for Influenza Medication
by Product - Percentage Breakdown of Value Sales for Zanamivir,
Oseltamivir, Peramivir, Amantadine, Rimantadine and Other
Products for the Years 2012, 2021 & 2027

Table 68: France Recent Past, Current & Future Analysis for
Influenza Medication by Distribution Channel - Hospitals,
Clinics and Pharmacies - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 69: France Historic Review for Influenza Medication by
Distribution Channel - Hospitals, Clinics and Pharmacies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 70: France 15-Year Perspective for Influenza Medication
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospitals, Clinics and Pharmacies for the Years 2012, 2021 &
2027

GERMANY
Influenza Medication Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2022 (E)
Table 71: Germany Recent Past, Current & Future Analysis for
Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 72: Germany Historic Review for Influenza Medication by
Product - Zanamivir, Oseltamivir, Peramivir, Amantadine,
Rimantadine and Other Products Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 73: Germany 15-Year Perspective for Influenza Medication
by Product - Percentage Breakdown of Value Sales for Zanamivir,
Oseltamivir, Peramivir, Amantadine, Rimantadine and Other
Products for the Years 2012, 2021 & 2027

Table 74: Germany Recent Past, Current & Future Analysis for
Influenza Medication by Distribution Channel - Hospitals,
Clinics and Pharmacies - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 75: Germany Historic Review for Influenza Medication by
Distribution Channel - Hospitals, Clinics and Pharmacies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 76: Germany 15-Year Perspective for Influenza Medication
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospitals, Clinics and Pharmacies for the Years 2012, 2021 &
2027

ITALY
Table 77: Italy Recent Past, Current & Future Analysis for
Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 78: Italy Historic Review for Influenza Medication by
Product - Zanamivir, Oseltamivir, Peramivir, Amantadine,
Rimantadine and Other Products Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 79: Italy 15-Year Perspective for Influenza Medication by
Product - Percentage Breakdown of Value Sales for Zanamivir,
Oseltamivir, Peramivir, Amantadine, Rimantadine and Other
Products for the Years 2012, 2021 & 2027

Table 80: Italy Recent Past, Current & Future Analysis for
Influenza Medication by Distribution Channel - Hospitals,
Clinics and Pharmacies - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 81: Italy Historic Review for Influenza Medication by
Distribution Channel - Hospitals, Clinics and Pharmacies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 82: Italy 15-Year Perspective for Influenza Medication by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Pharmacies for the Years 2012, 2021 &
2027

UNITED KINGDOM
Influenza Medication Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2022 (E)
Table 83: UK Recent Past, Current & Future Analysis for
Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 84: UK Historic Review for Influenza Medication by
Product - Zanamivir, Oseltamivir, Peramivir, Amantadine,
Rimantadine and Other Products Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 85: UK 15-Year Perspective for Influenza Medication by
Product - Percentage Breakdown of Value Sales for Zanamivir,
Oseltamivir, Peramivir, Amantadine, Rimantadine and Other
Products for the Years 2012, 2021 & 2027

Table 86: UK Recent Past, Current & Future Analysis for
Influenza Medication by Distribution Channel - Hospitals,
Clinics and Pharmacies - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 87: UK Historic Review for Influenza Medication by
Distribution Channel - Hospitals, Clinics and Pharmacies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 88: UK 15-Year Perspective for Influenza Medication by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Pharmacies for the Years 2012, 2021 &
2027

SPAIN
Table 89: Spain Recent Past, Current & Future Analysis for
Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 90: Spain Historic Review for Influenza Medication by
Product - Zanamivir, Oseltamivir, Peramivir, Amantadine,
Rimantadine and Other Products Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 91: Spain 15-Year Perspective for Influenza Medication by
Product - Percentage Breakdown of Value Sales for Zanamivir,
Oseltamivir, Peramivir, Amantadine, Rimantadine and Other
Products for the Years 2012, 2021 & 2027

Table 92: Spain Recent Past, Current & Future Analysis for
Influenza Medication by Distribution Channel - Hospitals,
Clinics and Pharmacies - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 93: Spain Historic Review for Influenza Medication by
Distribution Channel - Hospitals, Clinics and Pharmacies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 94: Spain 15-Year Perspective for Influenza Medication by
Distribution Channel - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Pharmacies for the Years 2012, 2021 &
2027

RUSSIA
Table 95: Russia Recent Past, Current & Future Analysis for
Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 96: Russia Historic Review for Influenza Medication by
Product - Zanamivir, Oseltamivir, Peramivir, Amantadine,
Rimantadine and Other Products Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 97: Russia 15-Year Perspective for Influenza Medication
by Product - Percentage Breakdown of Value Sales for Zanamivir,
Oseltamivir, Peramivir, Amantadine, Rimantadine and Other
Products for the Years 2012, 2021 & 2027

Table 98: Russia Recent Past, Current & Future Analysis for
Influenza Medication by Distribution Channel - Hospitals,
Clinics and Pharmacies - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 99: Russia Historic Review for Influenza Medication by
Distribution Channel - Hospitals, Clinics and Pharmacies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 100: Russia 15-Year Perspective for Influenza Medication
by Distribution Channel - Percentage Breakdown of Value Sales
for Hospitals, Clinics and Pharmacies for the Years 2012, 2021 &
2027

REST OF EUROPE
Table 101: Rest of Europe Recent Past, Current & Future
Analysis for Influenza Medication by Product - Zanamivir,
Oseltamivir, Peramivir, Amantadine, Rimantadine and Other
Products - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 102: Rest of Europe Historic Review for Influenza
Medication by Product - Zanamivir, Oseltamivir, Peramivir,
Amantadine, Rimantadine and Other Products Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 103: Rest of Europe 15-Year Perspective for Influenza
Medication by Product - Percentage Breakdown of Value Sales for
Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and
Other Products for the Years 2012, 2021 & 2027

Table 104: Rest of Europe Recent Past, Current & Future
Analysis for Influenza Medication by Distribution Channel -
Hospitals, Clinics and Pharmacies - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 105: Rest of Europe Historic Review for Influenza
Medication by Distribution Channel - Hospitals, Clinics and
Pharmacies Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 106: Rest of Europe 15-Year Perspective for Influenza
Medication by Distribution Channel - Percentage Breakdown of
Value Sales for Hospitals, Clinics and Pharmacies for the Years
2012, 2021 & 2027

ASIA-PACIFIC
Influenza Medication Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Table 107: Asia-Pacific Recent Past, Current & Future Analysis
for Influenza Medication by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 108: Asia-Pacific Historic Review for Influenza
Medication by Geographic Region - Australia, India, South Korea
and Rest of Asia-Pacific Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 109: Asia-Pacific 15-Year Perspective for Influenza
Medication by Geographic Region - Percentage Breakdown of Value
Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2021 & 2027

Table 110: Asia-Pacific Recent Past, Current & Future Analysis
for Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 111: Asia-Pacific Historic Review for Influenza
Medication by Product - Zanamivir, Oseltamivir, Peramivir,
Amantadine, Rimantadine and Other Products Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 112: Asia-Pacific 15-Year Perspective for Influenza
Medication by Product - Percentage Breakdown of Value Sales for
Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and
Other Products for the Years 2012, 2021 & 2027

Table 113: Asia-Pacific Recent Past, Current & Future Analysis
for Influenza Medication by Distribution Channel - Hospitals,
Clinics and Pharmacies - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 114: Asia-Pacific Historic Review for Influenza
Medication by Distribution Channel - Hospitals, Clinics and
Pharmacies Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 115: Asia-Pacific 15-Year Perspective for Influenza
Medication by Distribution Channel - Percentage Breakdown of
Value Sales for Hospitals, Clinics and Pharmacies for the Years
2012, 2021 & 2027

AUSTRALIA
Influenza Medication Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Australia for 2022 (E)
Table 116: Australia Recent Past, Current & Future Analysis for
Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 117: Australia Historic Review for Influenza Medication
by Product - Zanamivir, Oseltamivir, Peramivir, Amantadine,
Rimantadine and Other Products Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 118: Australia 15-Year Perspective for Influenza
Medication by Product - Percentage Breakdown of Value Sales for
Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine and
Other Products for the Years 2012, 2021 & 2027

Table 119: Australia Recent Past, Current & Future Analysis for
Influenza Medication by Distribution Channel - Hospitals,
Clinics and Pharmacies - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 120: Australia Historic Review for Influenza Medication
by Distribution Channel - Hospitals, Clinics and Pharmacies
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 121: Australia 15-Year Perspective for Influenza
Medication by Distribution Channel - Percentage Breakdown of
Value Sales for Hospitals, Clinics and Pharmacies for the Years
2012, 2021 & 2027

INDIA
Influenza Medication Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in India for 2022 (E)
Table 122: India Recent Past, Current & Future Analysis for
Influenza Medication by Product - Zanamivir, Oseltamivir,
Peramivir, Amantadine, Rimantadine and Other Products -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 123: India Historic Review for Influenza Medication by
Product - Zanamivir, Oseltamivir, Peramivir, Amantadine,
Rimantadine and Other Products Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 124: India 15-Year Perspective for Influenza Medication
by Product - Percentage Breakdown of Value Sales for Zanamivir,
Oseltamivir, Peramivir, Amantadine, Rimantadine and Other
Products for the Years 2012, 2021 & 2027

Table 125: India Recent Past, Current & Future Analysis for

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06044677/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001